Futura a step closer to TPR100 deal

Consumer healthcare product developer Futura Medical is in talks with a major pharmaceutical company on a licensing deal for its pain relief product, TPR100.The company interested in licensing TPR100 is the same one with which Futura announced an evaluation agreement in July 2009.Futura has received an advance payment of £50,000 while terms of the potential licensing deal are thrashed out.The company said the negotiations are expected to be finalised by the end of the first half of next year.The company said it is also making progress with PET500, its product designed to delay male ejaculation during sexual intercourse. The treatment has been modified to comply with the US Food and Drug Administration’s guidelines, and discussions with a number of potential partners are currently in progress.